… rituximab (Rituxan) plus gemcitabine and oxaliplatin (R-GemOx) in patients with … associate professor of medicine at The Warren Alpert Medical School of Brown … ] first-line treatment. This trial, [unlike] some other recently reported trials, enrolled high …

… of Medicine (Hematology) at Yale University. Transcript: The current treatment … changed among most lymphoma doctors. That is based off … , cytarabine, and cisplatin or oxaliplatin [R-DHAP] alternating with … , although we have clinical trials ongoing here, so we …

… -based agents (eg, oxaliplatin and cisplatin). One promising … nanoparticles are undergoing clinical trials, and several have … Nano-based approved pharmaceuticals for cancer treatment: present and … nanoparticles for drug delivery. Curr Opin Biotechnol. 2014;28 …

… (Rituxan) plus gemcitabine and oxaliplatin (R-GemOx) in patients … Regarding safety, the trial showed that treatment-related adverse events ( … least 5% between the treatment arms that were more … professor of medicine at The Warren Alpert Medical School of …

… associate professor of clinical medicine at Keck Medicine of USC, the … plus oxaliplatin] is probably the least offensive of these drugs in … plus lenalidomide [Revlimid], which is FDA approved, a CD19 [antibody] … it's not FDA approved for [the second …

… rituximab (Rituxan) plus gemcitabine and oxaliplatin (R-GemOx; HR, 0 … professor of medicine at The Warren Alpert Medical School of … efficacy results from the trial. Transcript: The trial had, interestingly, … , compared with some other trials, had access to CAR …

… , fluorouracil, irinotecan, and oxaliplatin at modified dosages (mFOLFIRINOX) … standard chemotherapy as treatment for patients with … mg/m2 of oxaliplatin, 400 mg/ … treatment, or uncontrolled intercurrent illness, among other reasons. The trial …

… Gynecologic Oncology Group trial 0241, which aimed … treatment regimen was modified to include albumin-bound paclitaxel, oxaliplatin … diagnostic strategies and precision medicine in mucinous ovarian carcinoma … : evidence from clinical trials. Int J Gynecologic …

… have found that oxaliplatin-based chemotherapy … drug offered no survival advantage and led to higher rates of treatment … University College of Medicine, conducted a … treatment discontinuation. In fact, almost 40% of older patients receiving oxaliplatin …

… agonist mitazalimab and modified FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and fluorouracil; … potential to become a transformative treatment option for patients with pancreatic … initiate a confirmatory phase 3 trial together with a partner. We …